Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Renal Clinical Trials Commercial

Farxiga CKD Trial Stopped Early For Efficacy, Giving The SGLT2 Inhibitor An Edge

Executive Summary

A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.

You may also be interested in...



AZ Takes Time To Answer EU Queries On Broadening Brilique Indication

EC Approves Extended Invokana Indication On Renal Outcomes In DKD

Mundipharma has announced the European Commission’s extension of the indications for Invokana to include renal outcomes data from the Phase III CREDENCE study.

AZ To Adopt Indication-Based Pricing For Farxiga In Heart Failure

AstraZeneca's biopharmaceuticals president Ruud Dobber tells Scrip that the price for Farxiga in the heart failure indication should reflect its potential to improve survival and reduce the need for hospitalization.

Table

View full table

Related Content

Scrip
Scrip
Scrip

Topics

Related Companies

Tags:
Renal Clinical Trials Commercial
Latest Headlines

Scrip M&A Podcast: Which Companies Could Be Acquired Next?

BMS Has A Strong Pipeline, But Access Challenges Remain

Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy

Takeda, Astellas Found New JV To Support Japanese Bioventures

See All
UsernamePublicRestriction

Register

SC141947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By